We are live on
!
Find out more
MIM
MetLife Investment Management Portfolio holdings
AUM
$19.6B
1-Year Est. Return
32.64%
This Fund
S&P 500
This Quarter
Est. Return
+9.11%
1 Year Est. Return
+32.64%
3 Year Est. Return
+107.14%
5 Year Est. Return
+140.16%
10 Year Est. Return
–
AUM
$10.9B
AUM Growth
+$354M
(+3.3%)
Cap. Flow
-$371M
Cap. Flow
% of AUM
-3.39%
Top 10 Holdings %
Top 10 Hldgs %
21.68%
Holding
2,365
New
95
Increased
251
Reduced
1,484
Closed
53
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NXP Semiconductors
NXPI
|
+$12.1M |
| 2 |
State Street SPDR S&P MIDCAP 400 ETF Trust
MDY
|
+$11.5M |
| 3 |
iShares Russell 2000 ETF
IWM
|
+$7.47M |
| 4 |
iShares Core US Aggregate Bond ETF
AGG
|
+$6.8M |
| 5 |
Neurocrine Biosciences
NBIX
|
+$5.09M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$65.3M |
| 2 |
Vanguard Short-Term Bond ETF
BSV
|
+$17.5M |
| 3 |
Plains All American Pipeline
PAA
|
+$17.4M |
| 4 |
Apple
AAPL
|
+$15.4M |
| 5 |
Targa Resources
TRGP
|
+$13.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.23% |
| 2 | Financials | 13.41% |
| 3 | Healthcare | 12.54% |
| 4 | Consumer Discretionary | 11.8% |
| 5 | Industrials | 9.81% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2276
Verastem
VSTM
$629M
| $59.6K | ﹤0.01% |
2,009
-4,524
| -69% | -$127K |
|
|
AKTS
2277
DELISTED
Akoustis Technologies Inc
AKTS
| $58.4K | ﹤0.01% |
4,380
-9,843
| -69% | -$143K |
|
2278
Viking Therapeutics
VKTX
$3.97B
| $57.8K | ﹤0.01% |
9,146
-20,668
| -69% | -$145K |
|
2279
Grid Dynamics Holdings
GDYN
$632M
| $56.5K | ﹤0.01% |
3,549
-8,411
| -70% | -$121K |
|
2280
Clarus
CLAR
$141M
| $56.3K | ﹤0.01% |
3,302
-7,115
| -68% | -$121K |
|
|
CPLG
2281
DELISTED
CorePoint Lodging Inc. Common Stock
CPLG
| $51.6K | ﹤0.01% |
+5,718
| New | +$46.5K |
|
|
BNFT
2282
DELISTED
Benefitfocus, Inc.
BNFT
| $49.1K | ﹤0.01% |
3,554
-8,239
| -70% | -$119K |
|
2283
Bridgewater Bancshares
BWB
$614M
| $47.8K | ﹤0.01% |
2,962
+223
| +8% | +$3.29K |
|
2284
Neurogene
NGNE
$738M
| $47K | ﹤0.01% |
191
-548
| -74% | -$140K |
|
2285
CytomX Therapeutics
CTMX
$760M
| $40.7K | ﹤0.01% |
5,262
-9,764
| -65% | -$77.3K |
|
|
GRTS
2286
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $40.1K | ﹤0.01% |
+4,256
| New | +$58.6K |
|
|
BRY
2287
DELISTED
Berry Corp
BRY
| $40K | ﹤0.01% |
+7,251
| New | +$35.7K |
|
|
CAMP
2288
DELISTED
CalAmp Corp.
CAMP
| $39.1K | ﹤0.01% |
157
-485
| -76% | -$123K |
|
|
DADA
2289
DELISTED
Dada Nexus
DADA
| $38.3K | ﹤0.01% |
+1,049
| New | +$39.9K |
|
|
SIEN
2290
DELISTED
Sientra, Inc.
SIEN
| $33.6K | ﹤0.01% |
+462
| New | +$29.5K |
|
|
VXRT
2291
DELISTED
Vaxart
VXRT
| $33.6K | ﹤0.01% |
5,557
-18,441
| -77% | -$142K |
|
|
PRTK
2292
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $32.7K | ﹤0.01% |
4,634
-16,106
| -78% | -$116K |
|
2293
Q32 Bio
QTTB
$458M
| $30.2K | ﹤0.01% |
178
-706
| -80% | -$149K |
|
2294
Spero Therapeutics
SPRO
$68.9M
| $29.9K | ﹤0.01% |
2,028
-7,402
| -78% | -$130K |
|
2295
KRONOS Worldwide
KRO
$905M
| $28.6K | ﹤0.01% |
1,866
-9,333
| -83% | -$140K |
|
|
CODX
2296
Co-Diagnostics
CODX
$5.45M
| $28.2K | ﹤0.01% |
99
-311
| -76% | -$124K |
|
2297
Standard BioTools
LAB
$312M
| $27K | ﹤0.01% |
5,977
-26,759
| -82% | -$147K |
|
|
EMWP
2298
DELISTED
Eros Media World PLC
EMWP
| $26.5K | ﹤0.01% |
733
-2,947
| -80% | -$118K |
|
2299
Viemed Healthcare
VMD
$353M
| $26.5K | ﹤0.01% |
2,616
-14,073
| -84% | -$132K |
|
2300
Puma Biotechnology
PBYI
$459M
| $23.3K | ﹤0.01% |
2,392
-11,399
| -83% | -$127K |
|
Similar funds
SPIA
BG
PCM
CS
HHII
LF
EIM
MetLife Investment Management's Q1 2021 Portfolio in Review
As of Q1 2021, MetLife Investment Management held 2,365 positions worth $10.9B, up 3.3% from $10.6B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
MetLife Investment Management withdrew a net $371M in Q1 2021, closing 53 positions and reducing 1,484 holdings. Its most notable exit was Plains All American Pipeline, an estimated $17.4M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 21% a quarter earlier, followed by Financials and Healthcare.
Against the trend, MetLife Investment Management opened a new position in NXP Semiconductors worth $13.3M.
- MetLife Investment Management's largest Q1 2021 buy was NXP Semiconductors: 66,011 shares worth $13.3M.
- MetLife Investment Management added most to State Street SPDR S&P MIDCAP 400 ETF Trust in Q1 2021, an estimated $11.5M increase.
- MetLife Investment Management's biggest Q1 2021 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $65.3M.
- MetLife Investment Management fully exited Plains All American Pipeline in Q1 2021, selling an estimated $17.4M.
- MetLife Investment Management's ten largest holdings make up 22% of its $10.9B portfolio in Q1 2021.
- MetLife Investment Management opened 95 new positions and closed 53 in Q1 2021.
- MetLife Investment Management's portfolio value rose 3.3% quarter-over-quarter to $10.9B.
Based on MetLife Investment Management's 13F filing for Q1 2021, filed 14 May 2021.